NCT04011865

Brief Summary

This study is to compare the outcomes of robotic-assisted laparoscopic radical prostatectomy (RARP) and laparoscopic radical prostatectomy (LRP) for prostate cancer treatment in terms of perioperative surgical, functional and oncological outcomes.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P25-P50 for not_applicable prostate-cancer

Timeline
Completed

Started Jan 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2019

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 13, 2019

Completed
2 months until next milestone

First Posted

Study publicly available on registry

July 9, 2019

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

July 14, 2020

Status Verified

July 1, 2020

Enrollment Period

2 years

First QC Date

May 13, 2019

Last Update Submit

July 12, 2020

Conditions

Keywords

laparoscopic radical prostatectomyrobotic-assisted laparoscopic radical prostatectomyprostate cancer

Outcome Measures

Primary Outcomes (21)

  • The console time

    The time which surgeon spends on the robot console by minuite

    During the surgery

  • Mean of blood loss

    Milliliter

    During the surgery

  • Perioperative transfusion rate (%)

    The number of cases which will be transfused.

    Up to 1 month after operation

  • The rate of positive surgical margins, extracapsular extension, seminal vesicle invasion, (5)perineural invasion, the number of lymph node yield and node involvement,

    Number of cases, based on the result of pathology.

    Up to 1 week after operation

  • Number of blood units transfused

    Milliliter

    Up to 1 week after operation

  • the rate of conversion to open surgery, the rate of intraoperative incidents (%),

    Percentage

    Up to 1 weeks after the surgery.

  • The postoperative recovery parameters using Numeric Pain Rating Scale (NPRS),

    The NPRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of pain, in a total of 10 points, higher score means worse, with 0 means no pain and 10 is the worst pain. The mean score will be calculated to reflect the post-operative pain.

    Up to 3 month after surgery

  • Change of hemoglobin from baseline

    (mg/mL)

    Up to 1 week after operation

  • The drainage time

    (day),

    Up to 3 months after surgery

  • To assess urethral catheter time, urethral catheter time

    (day)

    Up to 3 months after surgery

  • To assess bowel movement recovery time,

    (day)

    Up to 1 week after surgery

  • To assess postoperative hospital stay

    (day)

    Up to 1 month after surgery

  • The rate of postoperative complications (including infections)

    Percentage

    in day 3, day 7, and 1 month after surgery.

  • PSA level in blood

    (mg/mL)

    Before operation

  • PSA level in blood

    (mg/mL)

    6 weeks post-operation

  • PSA level in blood

    (mg/mL)

    3 months post-operation

  • PSA level in blood

    (mg/mL)

    6 months post-operation

  • PSA level in blood

    (mg/mL)

    12 months post-operation

  • local and regional recurrences on sonography

    including ultrasound when PSA rising or any indication of recurrent

    through study completion, an average of 1 year

  • local and regional recurrences, on MRI

    including MRI when PSA rising or any indication of recurrent

    through study completion, an average of 1 year

  • local and regional recurrences, on PET Scan

    including PET Scan, when PSA rising or any indication of recurrent

    through study completion, an average of 1 year

Secondary Outcomes (12)

  • Evaluating the pre and postoperative lower urinary tract symptoms using Full score of International Prostate Symptoms Scores (IPSS)

    Preoperative

  • Evaluating the pre and postoperative lower urinary tract symptoms using International Prostate Symptoms Scores (IPSS)

    3 months postoperative

  • Evaluating the pre and postoperative lower urinary tract symptoms using Full score of International Prostate Symptoms Scores (IPSS)

    6 months, postoperative

  • Evaluating the pre and postoperative lower urinary tract symptoms using Full score of International Prostate Symptoms Scores (IPSS)

    12 months postoperative.

  • Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score

    Preoperative

  • +7 more secondary outcomes

Study Arms (2)

Robotic-assisted surgery

ACTIVE COMPARATOR
Procedure: Radical prostatectomy

Laparoscopic surgery

SHAM COMPARATOR
Procedure: Radical prostatectomy

Interventions

The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.

Laparoscopic surgeryRobotic-assisted surgery

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult men aged 18 years and over;
  • Undergoing RARP or LRP. prostatectomy for prostate cancer at Binh Dan Hospital;
  • Clinically suitable for radical prostatectomy (cT1-3, No, Mo);
  • Cognitively able to give written informed consent for participation;
  • Elective procedure.

You may not qualify if:

  • The patient lacks the ability to consent for themselves;
  • Patients unwilling to undergo pre- and post-operative evaluation according to the protocol;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Binh Dan Hospital

Ho Chi Minh City, 700000, Vietnam

RECRUITING

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Officials

  • Hung V Tran, MD, PhD

    Binh Dan Hospital

    STUDY DIRECTOR

Central Study Contacts

Hoang PC Nguyen, Associate Professor, MD, PhD

CONTACT

Linh NK Tran, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 13, 2019

First Posted

July 9, 2019

Study Start

January 1, 2019

Primary Completion

December 31, 2020

Study Completion

December 31, 2020

Last Updated

July 14, 2020

Record last verified: 2020-07

Data Sharing

IPD Sharing
Will not share

Locations